SCHEMBL2836153

SCHEMBL2836153

COc1cc(C)c(S(=O)(=O)N2CCCCC2COc2nccc(N3CCC4(CCN(Cc5ccccc5)C4)C3)n2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 8/20 0.38
CYP3A4 P08684 7/20 0.38
TSHR P16473 4/20 0.38
CYP1A2 P05177 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
GHSR Q92847 1/20 0.37
CASP3 P42574 6/20 0.37
CASP7 P55210 5/20 0.37
USP2 O75604 1/20 0.36
MCHR1 Q99705 1/20 0.35
CASP2 P42575 2/20 0.35
CASP9 P55211 2/20 0.35
CASP1 P29466 1/20 0.35
CASP4 P49662 1/20 0.35
CASP6 P55212 1/20 0.35
CASP8 Q14790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835560 0.98 CASP3 (0.39) CYP2D6CYP3A4TSHRCYP1A2ALDH1A1
SCHEMBL2835785 0.88 CYP2D6 (0.37) CYP2D6CYP3A4TSHRCYP1A2ALDH1A1
SCHEMBL2832199 0.86 HCRTR2 (0.40) CASP3CASP7CASP2CASP9CASP1
SCHEMBL2835304 0.86 CASP3 (0.39) CYP2D6CYP3A4TSHRCYP1A2ALDH1A1
SCHEMBL2834128 0.84 HCRTR2 (0.41) CASP3CASP7CASP2CASP9CASP1
SCHEMBL2832054 0.83 KDM4E (0.37) ALDH1A1CASP3CASP7CASP2CASP9
SCHEMBL2833717 0.83 CASP3 (0.37) ALDH1A1CASP3CASP7CASP2CASP9
SCHEMBL2832257 0.83 CASP3 (0.40) CYP2D6CYP3A4TSHRCYP1A2ALDH1A1
SCHEMBL2832118 0.82 CASP3 (0.38) ALDH1A1CASP3CASP7CASP2CASP9
SCHEMBL2836668 0.81 ALDH1A1 (0.40) ALDH1A1HPGDCASP3CASP7CASP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS CYP2D6 1157/4885CYP3A4 1682/4885TSHR 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.